

News Release

Company name: H.U. Group Holdings, Inc.
Representative: Shigekazu Takeuchi, Director, President and Group CEO
Securities code: 4544 Prime Market, Tokyo Stock Exchange

Fujirebio obtains approval to a SARS-CoV-2 antigen rapid test for use as a general test drug

Tokyo, Japan, October 17, 2022 --- H.U. Group Holdings Inc. announced today that its wholly-owned subsidiary Fujirebio Inc. (President & CEO: Takeshi Fujita; Head Office: Shinjuku-ku, Tokyo; hereinafter "Fujirebio"), obtained on October 17, 2022, approval from the Ministry of Health, Labour and Welfare to manufacture and market ESPLINE[®] SARS-CoV-2 N, a rapid test for detecting novel coronavirus (SARS-CoV-2) antigens. For use as a general-use test drug (Class 1 OTC drug), the new product will be launched as soon as it is available for distribution.

A single kit of ESPLINE[®] SARS-CoV-2 N can be used to collect either nasal swab or saliva specimens. Specimens can provide results within 20 minutes.

As a general-use test drug (Class 1 OTC drug), the product will be available at pharmacies as well as online.

In May 2020, Fujirebio obtained approval from the Ministry of Health, Labour and Welfare to manufacture and market ESPLINE[®] SARS-CoV-2, Japan's first rapid test for detection of SARS-CoV-2 antigens, as an in-vitro diagnostic drug. Fujirebio markets the product to medical institutions and pharmacies. By providing ESPLINE[®] SARS-CoV-2 N for general use, Fujirebio aims to curb the spread of SARS-CoV-2.

Product Overview

Generic name: SARS-CoV-2 virus antigen kit for general use

Product name: ESPLINE[®] SARS-CoV-2 N (for general use)

Package: 2 tests

Designed for assays with: Nasal swab and saliva

Marketing authorization holder: Fujirebio Inc.

<Notes>

Be sure to receive explanation from a pharmacist and thoroughly read the precautions before using the test drug. If you tested positive, seek appropriate medical attention. If you tested negative but have COVID-like symptoms, seek appropriate medical attention.

Contacts:

For media:

Public Relations Section, Public Relations/Sustainability Dept.

Phone: +81-3-6279-0884

Email: pr@hugp.com

For investors and analysts:

IR/SR Dept.

Phone: +81-3-5909-3337

Email: ir@hugp.com